NTR6379.

Trial name or title	Shared decision making in patients with Castration‐Resistant Prostate Cancer ‐ the impact of implementation of a treatment decision aid in CRPC patients
Methods	RCT
Participants	Inclusion criteria Men who are newly diagnosed with CRPC. CRPC is defined as any cancer progression under maximal hormonal treatment with anti‐androgens and/or LHRH agonist or antagonist (when three consecutive rises of PSA are observed at castrate serum levels of testosterone (< 50 ng/dL or <1.7 nmol/L) and/or progression of osseous lesions is shown)) Patients are eligible for at least two treatment options Patients have to be able to make use of a computer with internet‐access in order to make use of the web‐based decision aid Patients have to be able to complete a Dutch questionnaire Exclusion criteria In the case of a second opinion the patient will not be included if the first opinion was obtained in one of the other involved hospitals and vice versa Patients who do not have sufficient knowledge of the Dutch language
Interventions	Decision aid with value clarification exercise
Outcomes	Primary outcomes Objective knowledge Informed choice Secondary outcomes Correlation between G8 score and treatment decision Correlation between TUG‐test and treatment decision Quality of life Anxiety Value clarification Satisfaction with decision making, information and treatment Preparation for decision making Healthcare providers' evaluation of decision aid Partner involvement in SDM Treatment outcome (e.g. dose reductions, treatment delays, treatment discontinuation, treatment switch, and death)
Starting date	September 2016
Contact information	Prof. Dr. J. J. M. Takkenberg, +31 (0)10 7035413, j.j.m.takkenberg@erasmusmc.nl
Notes